Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB-NK-301 in Advanced or Metastatic TROP2-Expressing Solid Tumors
NCT07589530Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of EB-NK-301 in solid tumor, sponsored by Biotech Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
EB-NK-301
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07589530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589530.